BOBAPP

品牌动态
集团实时动态,大健康领域前沿资讯
img
您現在的具体位置:
搜索引擎BOBAPP
/
/
/
同是仿制药,营养健康元“舒坦琳”有所不同去哪里?

同是仿制药,健康元“舒坦琳”不同在哪里?

  • 发布消息期限:2020-02-20 21:57
点击量:

【慨括描叙】作为被国(guo)内外指南推荐的(de)(de)(de)气(qi)道阻塞性(xing)(xing)疾(ji)病优选治(zhi)疗方(fang)法(fa),吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)疗法(fa)是(shi)临(lin)床主(zhu)流(liu)的(de)(de)(de)治(zhi)疗方(fang)式。然(ran)而,由于吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)制剂(ji)(ji)(ji)(ji)开发壁(bi)垒较(jiao)高,导致(zhi)国(guo)内有(you)能力(li)参与研(yan)发的(de)(de)(de)玩家较(jiao)少,在(zai)这(zhei)(zhei)场(chang)(chang)巅(dian)(dian)峰较(jiao)量(liang)(liang)(liang)(liang)(liang)中,2019年(nian)4月,健(jian)康(kang)元集(ji)团凭(ping)借首(shou)个通过(guo)一(yi)致(zhi)性(xing)(xing)评(ping)价的(de)(de)(de)呼吸(xi)(xi)(xi)(xi)(xi)疾(ji)病吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)制剂(ji)(ji)(ji)(ji),同(tong)(tong)时也是(shi)首(shou)个新4类注册获批的(de)(de)(de)雾(wu)化(hua)(hua)吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)溶(rong)(rong)(rong)液(ye)——吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异(yi)(yi)丙(bing)(bing)托溴(xiu)铵(an)溶(rong)(rong)(rong)液(ye)(舒(shu)坦琳(lin)),一(yi)举打破了(le)原(yuan)(yuan)研(yan)产(chan)(chan)品(pin)(pin)在(zai)国(guo)内多年(nian)来(lai)的(d🐭e)(de)(de)技术垄断,成为这(zhei)(zhei)场(chang)(chang)巅(dian)(dian)峰较(jiao)量(liang)(liang)(liang)(liang)(liang)中的(de)(de)(de)领(ling)跑者。那么,健(jian)康(kang)元的(de)(de)(de)吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异(yi)(yi)丙(bing)(bing)托溴(xiu)铵(an)溶(rong)(rong)(rong)液(ye)(舒(shu)坦琳(lin))到底有(you)何不同(tong)(tong)? 稳定(ding)(ding)(ding)性(xing)(xing)与原(yuan)(yuan)研(yan)产(chan)(chan)品(pin)(pin)相(xiang)当,有(you)关(guan)物(wu)质(zhi)(zhi)(杂质(zhi)(zhi))含量(liang)(liang)(liang)(liang)(liang)更低(di)吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异(yi)(yi)丙(bing)(bing)托溴(xiu)铵(an)溶(rong)(rong)(rong)液(ye)(舒(shu)坦琳(lin))采用(yong)(yong)目前国(guo)际最领(ling)先的(de)(de)(de)吹、灌、封一(yi)体化(hua)(hua)无菌制造技术,根(gen)据(ju)(ju)欧(ou)美质(zhi)(zhi)量(liang)(liang)(liang)(liang)(liang)要(yao)求,对(dui)(dui)产(chanꦓ)(chan)品(pin)(pin)质(zhi)(zhi)量(liang)(liang)(liang)(liang)(liang)进行了(le)严格(ge)控(kong)制。药(yao)物(wu)稳定(ding)(ding)(ding)性(xing)(xing)试(shi)验表明,该(gai)药(yao)物(wu)的(de)(de)(de)有(you)关(guan)物(wu)质(zhi)(zhi)(杂质(zhi)(zhi))变化(hua)(hua)趋势与原(yuan)(yuan)研(yan)产(chan)(chan)品(pin)(pin)一(yi)致(zhi),产(chan)(chan)品(pin)(pin)质(zhi)(zhi)量(liang)(liang)(liang)(liang)(liang)和稳定(ding)(ding)(ding)性(xing)(xing)与原(yuan)(yuan)研(yan)产(chan)(chan)品(pin)(pin)相(xiang)当,有(you)关(guan)物(wu)质(zhi)(zhi)(杂质(zhi)(zhi))含量(liang)(liang)(liang)(liang)(liang)更低(di)。 相(xiang)同(tong)(tong)给药(yao)时间及(ji)剂(ji)(ji)(ji)(ji)量(liang)(liang)(liang)(liang)(liang)下,药(yao)物(wu)吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)总量(liang)(liang)(liang)(liang)(liang)与原(yuan)(yuan)研(yan)产(chan)(chan)品(pin)(pin)相(xiang)当吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异(yi)(yi)丙(bing)(bing)托溴(xiu)铵(an)溶(rong)(rong)(rong)液(ye)(舒(shu)坦琳(lin))是(shi)由异(yi)(yi)丙(bing)(bing)托溴(xiu)铵(an)和沙(sha)丁(ding)胺(an)醇两个药(yao)物(wu)组(zu)成,可以同(tong)(tong)时作用(yong)(yong)于支气(qi)管扩(kuo)张中的(de)(de)(de)不同(tong)(tong)靶点,迅速扩(kuo)张主(zhu)支气(qi)管和细(xi)支气(qi)管,有(you)速效(xiao)(xiao)、强效(xiao)(xiao)、安(an)全、方(fang)便等特点。根(gen)据(ju)(ju)中国(guo)药(yao)典及(ji)欧(ou)洲药(yao)典相(xiang)关(guan)规定(ding)(ding)(ding),对(dui)(dui)吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)溶(rong)(rong)(rong)液(ye)雾(wu)化(hua)(hua)气(qi)溶(rong)(rong)(rong)胶的(de)(de)(de)粒(li)径分(fen)布(bu)进行微细(xi)粒(li)子剂(ji)(ji)(ji)(ji)量(liang)(liang)(liang)(liang)(liang)测(ce)定(ding)(ding)(ding),来(lai)评(ping)价吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异(yi)(yi)丙(bing)(bing)托溴(xiu)铵(an)溶(rong)(rong)(rong)液(ye)(舒(shu)坦琳(lin))与原(yuan)(yuan)研(yan)产(chan)(chan)品(pin)(pin)的(de)(de)(de)空气(qi)动(dong)(dong)力(li)学(xue)粒(li)径分(fen)布(bu),结果显示,异(yi)(yi)丙(bing)(bing)托溴(xiu)铵(an)和沙(sha)丁(ding)胺(an)醇的(de)(de)(de)空气(qi)动(dong)(dong)力(li)学(xue)粒(li)径分(fen)布(bu)均与原(yuan)(yuan)研(yan)产(chan)(chan)品(pin)(pin)一(yi)致(zhi),该(gai)药(yao)物(wu)在(zai)相(xiang)同(tong)(tong)给药(yao)时间及(ji)剂(ji)(ji)(ji)(ji)量(liang)(liang)(liang)(liang)(liang)下,药(yao)物(wu)吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)总量(liang)(liang)(liang)(liang)(liang)与原(yuan)(yuan)研(yan)产(chan)(chan)品(pin)(pin)相(xiang)当。 作为这(zhei)(zhei)场(chang)(chang)巅(dian)(dian)峰较(jiao)量(liang)(liang)(liang)(liang)(liang)的(de)(de)(de)领(ling)跑者,“舒(shu)坦琳(lin)”仅仅是(shi)一(yi)个开始(shi)。目前健(jian)康(kang)元集(ji)团在(zai)研(yan)的(de)(de)(de)吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)制剂(ji)(ji)(ji)(ji)产(chan)(chan)品(pin)(pin)已超过(guo)20余种,未(wei)来(lai)一(yi)系列(lie)即将(jiang)上市的(de)(de)(de)吸(xi)(xi)(xi)(xi)(xi)入(ru)(ru)(ru)制剂(ji)(ji)(ji)(ji)产(chan)(chan)品(pin)(pin),也将(jiang)助(zhu)力(li)健(jian)康(kang)元成为这(zhei)(zhei)场(chang)(chang)巅(dian)(dian)峰较(jiao)量(liang)(liang)(liang)(liang)(liang)的(de)(de)(de)获胜者。 来(lai)源:医(yi)脉通儿科

同是仿制药,健康元“舒坦琳”不同在哪里?

【内容(rong)提要描素(su)】作为被(bei)国(guo)(guo)内外指(zhi)南推荐(jian)的(de)(de)(de)(de)气(qi)(qi)道(dao)阻塞性(xing)疾病优(you)选治(zhi)疗方(fang)法(fa),吸(xi)(xi)入(ru)(ru)(ru)疗法(fa)是(shi)临床(chuang)主流(liu)的(de)(de)(de)(de)治(zhi)疗方(fang)式。然而(er),由于(yu)吸(xi)(xi)入(ru)(ru)(ru)制(zhi)(zhi)剂(ji)(ji)开(kai)发壁垒(lei)较高,导致国(guo)(guo)内有能力(li)(li)参(can)与(yu)研(yan)发的(de)(de)(de)(de)玩家较少,在(zai)(zai)这(zhei)场(chang)(chang)巅(dian)(dian)(dian)峰(feng)(feng)较量(liang)(liang)(liang)(liang)(liang)(liang)中(zhong),2019年4月(yue),健(jian)康元(yuan)集团凭借首个(ge)通过一(yi)(yi)致性(xing)评价(jia)的(de)(de)(de)(de)呼吸(xi)(xi)疾病吸(xi)(xi)入(ru)(ru)(ru)制(zhi)(zhi)剂(ji)(ji),同(tong)(tong)时(shi)(shi)也是(shi)首个(ge)新4类注册获批的(de)(de)(de)(de)雾(wu)(wu)化吸(xi)(xi)入(ru)(ru)(ru)溶液(ye)(ye)——吸(xi)(xi)入(ru)(ru)(ru)用(yong✤)(yong)复(fu)(fu)方(fang)异丙(bing)托溴(xiu)铵(an)(an)(an)溶液(ye)(ye)(舒坦(tan)琳(lin)(lin)),一(yi)(yi)举打破了原(yuan)(yuan)(yuan)(yuan)研(yan)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)在(zai)(zai)国(guo)(guo)内多年来(lai)的(de)(de)(de)(de)技(ji)术垄断(duan),成为这(zhei)场(chang)(chang)巅(dian)(dian)(dian)峰(feng)(feng)较量(liang)(liang)(liang)(liang)(liang)(liang)中(zhong)的(de)(de)(de)(de)领(ling)跑(pao)(pao)者。那么,健(jian)康元(yuan)的(de)(de)(de)(de)吸(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异丙(bing)托溴(xiu)铵(an)(an)(an)溶液(ye)(ye)(舒坦(tan)琳(lin)(lin))到底有何不同(tong)(tong)? 稳定(ding)性(xing)与(yu)原(yuan)(yuan)(yuan)(yuan)研(yan)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)相(xiang)当,有关物(wu)(wu)(wu)质(杂(za)(za)质)含量(liang)(liang)(liang)(liang)(liang)(liang)更(geng)低吸(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异丙(bing)托溴(xiu)铵(an)(an)(an)溶液(ye)(ye)(舒坦(tan)琳(lin)(lin))采用(yong)(yong)目前(qian)国(guo)(guo)际最领(ling)先的(de)(de)(de)(de)吹、灌、封一(yi)(yi)体(ti)化无(wu)菌(jun)制(zhi)(zhi)造技(ji)术,根(gen)据欧(ou)美(mei)质量(liang)(liang)(liang)(liang)(liang)(liang)要求,对(dui)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)质量(liang)(liang)(liang)(liang)(liang)(liang)进行了严格控制(zhi)(zhi)。药(yao)(yao)(yao)物(wu)(wu)(wu)稳定(ding)性(xing)试验(yan)表明,该药(yao)(yao)(yao)物(wu)(wu)(wu)的(de)(de)(de)(de)有关物(wu)(wu)(wu)质(杂(za)(za)质)变化趋势(shi)与(yu)原(yuan)(yuan)(yuan)(yuan)研(yan)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)一(yi)(yi)致,产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)质量(liang)(liang)(liang)(liang)(liang)(liang)和(he)稳定(ding)性(xing)与(yu)原(yuan)(yuan)(yuan)(yuan)研(yan)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)相(xiang)当,有关物(wu)(wu)(wu)质(杂(za)(za)质)含量(liang)(liang)(liang)(liang)(liang)(liang)更(geng)低。 相(xiang)同(tong)(tong)给药(yao)(yao)(yao)时(shi)(shi)间及(ji)剂(ji)(ji)量(liang)(liang)(liang)(liang)(liang)(liang)下(xia),药(yao)(yao)(yao)物(wu)(wu)(wu)吸(xi)(xi)入(ru)(ru)(ru)总量(liang)(liang)(liang)(liang)(liang)(liang)与(yu)原(yuan)(yuan)(yuan)(yuan)研(yan)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)相(xiang)当吸(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异丙(bing)托溴(xiu)铵(an)(an)(an)溶液(ye)(ye)(舒坦(tan)琳(lin)(lin))是(shi)由异丙(bing)托溴(xiu)铵(an)(an)(an)和(he)沙丁胺醇(chun)两(liang)个(ge)药(yao)(yao)(yao)物(wu)(wu)(wu)组(zu)成,可以同(tong)(tong)时(shi)(shi)作用(yong)(yong)于(yu)支(zhi)(zhi)气(qi)(qi)管(guan)(guan)扩张(zhang)中(zhong)的(de)(de)(de)(de)不同(tong)(tong)靶点,迅(xun)速扩张(zhang)主支(zhi)(zhi)气(qi)(qi)管(guan)(guan)和(he)细(xi)支(zhi)(zhi)气(qi)(qi)管(guan)(guan),有速效、强(qiang)效、安(an)全、方(fang)便等特点。根(gen)据中(zhong)国(guo)(guo)药(yao)(yao)(yao)典(dian)及(ji)欧(ou)洲药(yao)(yao)(yao)典(dian)相(xiang)关规(gui)定(ding),对(dui)吸(xi)(xi)入(ru)(ru)(ru)溶液(ye)(ye)雾(wu)(wu)化气(qi)(qi)溶胶的(de)(de)(de)(de)粒(li)径(jing)分布(bu)进行微细(xi)粒(li)子(zi)剂(ji)(ji)量(liang)(liang)(liang)(liang)(liang)(liang)测定(ding),来(lai)评价(jia)吸(xi)(xi)入(ru)(ru)(ru)用(yong)(yong)复(fu)(fu)方(fang)异丙(bing)托溴(xiu)铵(an)(an)(an)溶液(ye)(ye)(舒坦(tan)琳(lin)(lin))与(yu)原(yuan)(yuan)(yuan)(yuan)研(yan)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)的(de)(de)(de)(de)空(kong)气(qi)(qi)动力(li)(li)学粒(li)径(jing)分布(bu),结果显示,异丙(bing)托溴(xiu)铵(an)(an)(an)和(he)沙丁胺醇(chun)的(de)(de)(de)(de)空(kong)气(qi)(qi)动力(li)(li)学粒(li)径(jing)分布(bu)均与(yu)原(yuan)(yuan)(yuan)(yuan)研(yan)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)一(yi)(yi)致,该药(yao)(yao)(yao)物(wu)(wu)(wu)在(zai)(zai)相(xiang)同(tong)(tong)给药(yao)(yao)(yao)时(shi)(shi)间及(ji)剂(ji)(ji)量(liang)(liang)(liang)(liang)(liang)(liang)下(xia),药(yao)(yao)(yao)物(wu)(wu)(wu)吸(xi)(xi)入(ru)(ru)(ru)总量(liang)(liang)(liang)(liang)(liang)(liang)与(yu)原(yuan)(yuan)(yuan)(yuan)研(yan)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)相(xiang)当。 作为这(zhei)场(chang)(chang)巅(dian)(dian)(dian)峰(feng)(feng)较量(liang)(liang)(liang)(liang)(liang)(liang)的(de)(de)(de)(de)领(ling)跑(pao)(pao)者,“舒坦(tan)琳(lin)(lin)”仅仅是(shi)一(yi)(yi)个(ge)开(kai)始。目前(qian)健(jian)康元(yuan)集团在(zai)(zai)研(yan)的(de)(de)(de)(de)吸(xi)(xi)入(ru)(ru)(ru)制(zhi)(zhi)剂(ji)(ji)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin)已(yi)超(chao)过20余种,未来(lai)一(yi)(yi)系列(lie)即将(jiang)上(shang)市的(de)(de)(de)(de)吸(xi)(xi)入(ru)(ru)(ru)制(zhi)(zhi)剂(ji)(ji)产(chan)(chan)(chan)品(pin)(pin)(pin)(pin)(pin),也将(jiang)助力(li)(li)健(jian)康元(yuan)成为这(zhei)场(chang)(chang)巅(dian)(dian)(dian)峰(feng)(feng)较量(liang)(liang)(liang)(liang)(liang)(liang)的(de)(de)(de)(de)获胜者。 来(lai)源:医脉通儿科(ke)

  • 发布新闻時间:2020-02-20 21:57
  • 考察量:
详情
当做被国內外规范举荐的吸呼道赌塞性病症甄选进行医疗技巧,误吸医疗玩法是临床医学中低端的进行医疗玩法。因此,因为误吸药物药制剂设计掣肘较高,会造成国內有本事参与的新护肤品开发的朋友较少,在一场颠峰交锋中,二零一九年4月,稳定元集团电话凭借着正式启动凭借不对性评估的吸呼病症误吸药物药制剂,互相也是正式启动新4类注册成功应用的雾化吸取到误吸溶剂——误吸用复方异丙托溴铵溶剂(舒坦琳),一次摆脱了原研护肤品在国內5年来的技术设备专卖,被选为一场颠峰交锋中的领航者。特别,稳定元的误吸用复方异丙托溴铵溶剂(舒坦琳)到底应该有无其他?  

稳定性与原研产品相当,有关物质(杂质)含量更低

吸气用复方异丙托溴铵水溶液(舒坦琳)适用现在国外最领先于的吹、灌、封分离式化无菌室制造厂技木,要根据外国品質标准要求,对產品品質对其进行了严格规范调控。抗癫痫药物治疗维持性试验报告表述,该抗癫痫药物治疗的相关的英文有害元素(沉淀物)变现态势与原研產品统一,產品品質和维持性与原研產品比较,相关的英文有害元素(沉淀物)的含量更低。  

相同给药时间及剂量下,药物吸入总量与原研产品相当

吸取到用复方异丙托溴铵水氢氧化钠氢氧化钠溶液(舒坦琳)是由异丙托溴铵和沙丁胺醇两种类抗癫痫药物剂量构造,还可以同一用途于支气管扩展中的有所不同靶点,快速发展扩展主支气管和细支气管,有速效、强力、安全防护、简单方便等优势。依照国药典及英国药典对应明文规定,对吸取到水氢氧化钠氢氧化钠溶液做雾化气溶胶的粒级规划图制作实施微细颗粒的用药量校正,来好评吸取到用复方异丙托溴铵水氢氧化钠氢氧化钠溶液(舒坦琳)与原研软件的环境趋势系统学粒级规划图制作,的结果出现,异丙托溴铵和沙丁胺醇的环境趋势系统学粒级规划图制作均与原研软件相等于,该类抗癫痫药物剂量在相等于给药時间及的用药量下,类抗癫痫药物剂量吸取到消费量与原研软件相等于。   用作刺激性天梯角逐的健跑者,“舒坦琳”并不是是一种个逐渐。现如今建康元群体在研的吸到药物的软件已低于20余个,的前景一一整套即 :将成功上市的吸到药物的软件,也将促动建康元称为刺激性天梯角逐的大获全胜者。   来源于:医脉通儿科门诊

扫动态二维码(ma)用手掌机看

高速导航仪

服务的咨询(xun)热线

业(ye)务(wu)服务(wu)电话

Copyright © 建康元药🤪业(ye)集(ji)团网站平(p💜ing)台司(si)股票(piao)现(xian)有司(si)    All Rights Reserved.     网站平(ping)台建成:      

乐鱼全站官网登录|网页版 乐鱼全站app下载|官网入口 乐鱼全站官网登录 - BOBAPP - 欢迎您 乐鱼全站官网登录 - 网页登录BOBAPP leyu乐鱼体育官网-BOBAPP